Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
企業コードLGND
会社名Ligand Pharmaceuticals Inc
上場日Nov 18, 1992
最高経営責任者「CEO」Mr. Todd C. Davis
従業員数68
証券種類Ordinary Share
決算期末Nov 18
本社所在地555 Heritage Drive, Suite 200
都市JUPITER
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号33458
電話番号18585507500
ウェブサイトhttps://www.ligand.com/
企業コードLGND
上場日Nov 18, 1992
最高経営責任者「CEO」Mr. Todd C. Davis
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし